Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 133.9M |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | 2.2 |
| P/S (ttm) | |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 5% |
| Held by Institutions % | 12% |
| 1 Day Vol Adjusted Return | -0.7 |
| 1 Month Vol Adjusted Return | -5.6 |
| 3 Month Vol Adjusted Return | -9.9 |
| 6 Month Vol Adjusted Return | -16.7 |
| 20 Days SMA Price ZScore | -1.6 |
| 50 Days SMA Price ZScore | -2.5 |
| 12 -26 Days PPO | -6.2 |
| 1 Month Average Short Volume Ratio | 41.6 |
| 1 Day Volume Change ZScore | -1.2 |
| 1 Month Daily Vol | 3.4 |
Stock news
BEDMINSTER, N.J., November 08, 2021--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second fiscal quarter ended September 30, 2021.
BEDMINSTER, N.J., November 02, 2021--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the Jefferies London Healthcare Conference as follows:
BEDMINSTER, N.J., October 27, 2021--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET.
BEDMINSTER, N.J., September 27, 2021--TYME Technologies, Inc. ("TYME" or the "Company") (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first patient has been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative ("HR+/HER2-") breast cancer who previously received a CDK4/6 inhibitor regimen being conducted by Georgetown University
Every investor in Tyme Technologies, Inc. ( NASDAQ:TYME ) should be aware of the most powerful shareholder groups...
BEDMINSTER, N.J., September 02, 2021--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows: